Iterum Therapeutics PLC (ITRM) has a current Price-to-Book (P/B) ratio of -2.09. Compared to its 3-year average P/B ratio of -3.26, the current P/B ratio is approximately -35.96% higher. Relative to its 5-year average P/B ratio of -1.02, the current P/B ratio is about 105.45% higher. Iterum Therapeutics PLC (ITRM) has a Forward Free Cash Flow (FCF) yield of approximately -117.63%. Compared to its 3-year average FCF yield of -137.39%, the current FCF yield is approximately -14.39% lower. Relative to its 5-year average FCF yield of -98.76%, the current FCF yield is about 19.11% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for ITRM competitors is 0.49, providing a benchmark for relative valuation. Iterum Therapeutics PLC Corp (ITRM.O) exhibits a P/S ratio of 2.68, which is 446.38% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of ITRM increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of ITRM in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is ITRM currently overvalued or undervalued?

What is Iterum Therapeutics PLC (ITRM) fair value?

ITRM's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Iterum Therapeutics PLC (ITRM) is between 0.15 to 0.25 according to relative valuation method.

How does ITRM's valuation metrics compare to the industry average?

The average P/S ratio for ITRM's competitors is 0.49, providing a benchmark for relative valuation. Iterum Therapeutics PLC Corp (ITRM) exhibits a P/S ratio of 2.68, which is 446.38% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Iterum Therapeutics PLC (ITRM) as of Mar 04 2026?

As of Mar 04 2026, Iterum Therapeutics PLC (ITRM) has a P/B ratio of -2.09. This indicates that the market values ITRM at -2.09 times its book value.

What is the current FCF Yield for Iterum Therapeutics PLC (ITRM) as of Mar 04 2026?

As of Mar 04 2026, Iterum Therapeutics PLC (ITRM) has a FCF Yield of -117.63%. This means that for every dollar of Iterum Therapeutics PLC's market capitalization, the company generates -117.63 cents in free cash flow.

What is the current Forward P/E ratio for Iterum Therapeutics PLC (ITRM) as of Mar 04 2026?

As of Mar 04 2026, Iterum Therapeutics PLC (ITRM) has a Forward P/E ratio of -0.72. This means the market is willing to pay $-0.72 for every dollar of Iterum Therapeutics PLC's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Iterum Therapeutics PLC (ITRM) as of Mar 04 2026?

As of Mar 04 2026, Iterum Therapeutics PLC (ITRM) has a Forward P/S ratio of 2.68. This means the market is valuing ITRM at $2.68 for every dollar of expected revenue over the next 12 months.

ITRM Valuation